Table 1.

Demographics and treatment outcomes

ID #	Age	Gender	Ethnicity	Genotype	Pre-treatment HCV RNA (IU/ml)	Treatment Weeks	RVR	SVR
Incarcerated Cohort
1	21	M	Caucasian	1a	363,000	22	yes	yes
2	31	M	Caucasian	1a	22,200	24	yes	yes
3	29	M	Caucasian	1a	93,699	25	yes	yes
4	25	F	Caucasian	2b	1,665,560	15	yes	yes
5	34	M	Caucasian	1a	252,532	24	yes	yes
6	41	M	Caucasian	4a	88,574	24	yes	yes
7	29	M	Caucasian	3a	834,400	26	yes	yes
8	35	M	Caucasian/Hispanic	1a	32,366	16	yes	yes
9	24	M	Caucasian	1a	261,437	24	yes	yes
10	19	F	Caucasian	1a	131,819	24	yes	viral breakthrough
11	32	M	Caucasian	1a	546,478	20	no	viral breakthrough
12	30	M	Caucasian	4acd	1,590	16	yes	lost to follow up
13	24	F	Caucasian	3a	190,778	12	yes	lost to follow up
14	39	M	Caucasian	3a	93,185	12	yes	yes
15	40	M	Caucasian	1a	1,790,000	28	yes	no
Community Cohort
16	63	F	Caucasian	1	95,800	12	yes	yes
17	36	M	Caucasian	1b	1,230	24	yes	yes
18	20	F	Caucasian	1a	235,000	24	yes	yes
19	26	F	Caucasian	1a	648	24	yes	yes
20	20	M	Caucasian/Black	1ab	> 700000	48	no	yes
21	27	M	Caucasian	1	292,000	24	yes	lost to follow up
22	29	M	Caucasian	1	> 700000	48	yes	yes
23	20	F	Caucasian	1	> 700000	24	yes	yes
24	40	F	Caucasian	3a	> 700000	12	yes	yes
25	41	M	Hispanic	3a	1,385	24	yes	yes

^*HCV RNA monitoring of patient 1 utilized bDNA Quantiplex, Chiron Corporation for all time points.

^**A course of 48 weeks of therapy was recommended to patient 15 who delayed treatment for 27 months due to depression; he self-discontinued treatment after 27 weeks with subsequent virologic rebound.

^***Patient 22 and 25 were HIV seropositive.